What is Leerink Partnrs’ Forecast for ABCL Q1 Earnings?

AbCellera Biologics Inc. (NASDAQ:ABCL) – Analysts at Leerink Partnrs issued their Q1 2026 earnings per share (EPS) estimates for shares of AbCellera Biologics in a report released on Wednesday, April 16th. Leerink Partnrs analyst P. Souda anticipates that the company will post earnings per share of ($0.16) for the quarter. The consensus estimate for AbCellera Biologics’ current full-year earnings is ($0.59) per share. Leerink Partnrs also issued estimates for AbCellera Biologics’ Q2 2026 earnings at ($0.16) EPS, Q3 2026 earnings at ($0.17) EPS and Q4 2026 earnings at ($0.17) EPS.

Other equities analysts have also issued research reports about the stock. KeyCorp increased their price target on shares of AbCellera Biologics from $4.00 to $5.00 and gave the stock an “overweight” rating in a report on Wednesday. Benchmark reissued a “hold” rating on shares of AbCellera Biologics in a research note on Monday, March 3rd. Finally, Stifel Nicolaus dropped their price target on AbCellera Biologics from $12.00 to $10.00 and set a “buy” rating for the company in a research note on Friday, February 28th.

AbCellera Biologics Trading Up 1.3 %

Shares of NASDAQ ABCL opened at $2.42 on Friday. The business has a 50-day moving average of $2.51 and a 200-day moving average of $2.77. The firm has a market capitalization of $721.13 million, a price-to-earnings ratio of -3.97 and a beta of 0.50. AbCellera Biologics has a 12 month low of $1.89 and a 12 month high of $4.34.

Institutional Investors Weigh In On AbCellera Biologics

A number of institutional investors have recently made changes to their positions in ABCL. Janney Montgomery Scott LLC purchased a new position in AbCellera Biologics in the 1st quarter worth $29,000. GEM Asset Management LLC bought a new stake in AbCellera Biologics in the first quarter valued at approximately $63,000. Salem Investment Counselors Inc. lifted its position in AbCellera Biologics by 7.0% in the first quarter. Salem Investment Counselors Inc. now owns 78,800 shares of the company’s stock valued at $176,000 after purchasing an additional 5,150 shares during the last quarter. Squarepoint Ops LLC boosted its stake in shares of AbCellera Biologics by 333.1% during the fourth quarter. Squarepoint Ops LLC now owns 57,685 shares of the company’s stock valued at $169,000 after purchasing an additional 44,367 shares during the period. Finally, Two Sigma Advisers LP increased its stake in shares of AbCellera Biologics by 19.8% in the fourth quarter. Two Sigma Advisers LP now owns 2,608,400 shares of the company’s stock worth $7,643,000 after buying an additional 430,800 shares during the period. Hedge funds and other institutional investors own 61.42% of the company’s stock.

AbCellera Biologics Company Profile

AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company’s preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.